Karin Hamberg, who is currently executive vice president of drug delivery research and alliance & project management, will assume responsibility for clinical, regulatory, and medical affairs undertaking Dr Beckert’s responsibilities. Dr Hamberg will be registered with the Danish Commerce and Companies Agency as member of the management board.
Prior to joining LifeCycle Pharma (LCP), Dr Hamberg served as vice president of development at Leo Pharma, where she held various management positions within development and R&D project management for 15 years. She obtained her medical degree from University of Copenhagen and holds several diplomas including a Swiss diploma in pharmaceutical medicine.
Claus Braestrup, chairman of the board at LCP, said: “I am very pleased to announce that Karin will take responsibility of clinical, regulatory and medical affairs. We are in an exciting stage of development, and we are very much looking forward to utilizing Karin’s knowledge and experience in collaboration with those of our other experienced executive team members within the company.”